(Q38074826)

28 August 2017

1 reference

title

Statins in nonalcoholic fatty liver disease and steatohepatitis: updated review (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

28 August 2017

0 references

1 reference

1 reference

William Nseir

1

1 reference

28 August 2017

Mahmud Mahamid

series ordinal

2

1 reference

28 August 2017

language of work or name

1 reference

1 March 2013

1 reference

Current Atherosclerosis Reports

28 August 2017

published in

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

3

1 reference

28 August 2017

page(s)

305

1 reference

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Nonalcoholic fatty liver disease and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Body fat topography as an independent predictor of fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Fatty infiltration of liver in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Apolipoprotein synthesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Use of statins in patients with liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Overproduction of large VLDL particles is driven by increased liver fat content in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Soft drinks consumption and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Nonalcoholic fatty liver disease: the potential role of nutritional management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Review: The role of insulin resistance in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Statins as anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

Efficacy of rosuvastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-012-0305-5

The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis

21 January 2018

1 reference

12 December 2020

Randomised clinical trial: simvastatin as adjuvant therapy improves significantly the Helicobacter pylori eradication rate--a placebo-controlled study

1 reference

12 December 2020

In Vivo Stimulation of Low-Density Lipoprotein Degradation by Insulin

1 reference

12 December 2020

Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome

1 reference

12 December 2020

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

1 reference

12 December 2020

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

1 reference

12 December 2020

Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study

1 reference

12 December 2020

Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis.

1 reference

12 December 2020

A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Beyond the laboratory: clinical implications for statin pleiotropy

1 reference

12 December 2020

Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.

1 reference

12 December 2020

The impact of prior long-term versus short-term statin use on the mortality of bacteraemic patients

1 reference

12 December 2020

10.1007/S11883-012-0305-5

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1027404191

0 references

1 reference